Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2029

Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2029

Summary

Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease and is a serious chronic condition that affects the tissue surrounding the air sacs, or alveoli, in the lungs. This condition occurs when the lung tissue becomes thick and stiff for unknown reasons. Over time, breathing becomes difficult due to fibrosis caused by permanent scarring in the lungs (NHLBI, 2019). IPF is associated with a poor prognosis, with a median survival of three to five years (Raghu et al., 2011). There is currently no cure for IPF. However, certain medicines may slow the progression of IPF, which may extend the lifespan and improve the quality of life for people who have the disease (NHLBI, 2019).

GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals to build the forecast. GlobalData epidemiologists used sources that confirmed IPF cases through both a biopsy of the lung and high-resolution computed tomography (HRCT). The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent (total and diagnosed) cases of IPF in the 7MM, segmented by age, sex, severity, and comorbidities.

The following data describes epidemiology of IPF. In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of IPF from 28,301 cases in 2019 to 32,997 cases in 2019, at an AGR of 1.66% over the forecast period. The diagnosed prevalent cases of IPF in the 7MM will increase from 130,822 cases in 2019 to 153,747 cases in 2029, at an AGR of 1.75% over the forecast period. The total prevalent cases of IPF in the 7MM will increase from 201,698 cases in 2019 to 237,113 cases in 2029, at an AGR of 1.76% over the forecast period. IPF is more common in men, and the incidence and prevalence of IPF typically increases with advancing age. These trends are reflected in GlobalData’s forecast for the diagnosed incident and prevalent (total and diagnosed) cases for the 7MM.

Scope

  • The Idiopathic Pulmonary Fibrosis (IPF) Epidemiology Report provides an overview of the risk factors and global trends of IPF in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent cases of IPF (total and diagnosed) segmented by sex and age (ages ≥18 years). The prevalent cases of IPF (total and diagnosed) are also segmented by severity (mild, moderate, and severe), and comorbidities (pulmonary hypertension, chronic obstructive pulmonary disease, lung cancer, sleep apnea, pulmonary embolism, gastro-esophageal reflux disease, and depression). In addition, the model corresponding to this report includes age- and sex-specific mortality for IPF for ages 18 years and older.
  • The IPF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Buy

The Idiopathic Pulmonary Fibrosis Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global IPF market.
  • Quantify patient populations in the global IPF market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IPF therapeutics in each of the markets covered.
  • Understand magnitude of IPF population by severity at diagnosis.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Idiopathic Pulmonary Fibrosis: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for IPF (2019-2029)
3.5.1 Diagnosed Incident Cases of IPF
3.5.2 Sex-Specific Diagnosed Incident Cases of IPF
3.5.3 Age-Specific Diagnosed Incident Cases of IPF
3.5.4 Diagnosed Prevalent Cases of IPF
3.5.5 Sex-Specific Diagnosed Prevalent Cases of IPF
3.5.6 Age-Specific Diagnosed Prevalent Cases of IPF
3.5.7 Diagnosed Prevalent Cases of IPF by Severity
3.5.8 Diagnosed Prevalent Cases of IPF by Comorbidities
3.5.9 Total Prevalent Cases of IPF
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Coronavirus Disease 2019 (COVID-19) Impact
3.6.3 Limitations of the Analysis
3.6.4 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research - Prescriber Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About GlobalData
4.5 Contact Us
4.6 Disclaimer
List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for IPF
Table 4: Diagnosed Prevalent Cases of IPF by Comorbidities, N, Both Sexes, Ages ≥18 Years, 2019
Table 5: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2020
List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of IPF, Both Sexes, Ages ≥18 Years, 2019 and 2029
Figure 2: 7MM, Diagnosed Prevalent Cases of IPF, Both Sexes, Ages ≥18 Years, 2019 and 2029
Figure 3: 7MM, Diagnosed Incidence of IPF (Cases per 100,000 Population), Both Sexes, Ages ≥18 Years, 2019
Figure 4: 7MM, Diagnosed Prevalence of IPF, Both Sexes, Ages ≥18 Years, 2019
Figure 5: 7MM, Total Prevalence of IPF, Both Sexes, Ages ≥18 Years, 2019
Figure 6: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of IPF
Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF by Severity
Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF by Comorbidities
Figure 9: 7MM, Diagnosed Incident Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
Figure 10: 7MM, Diagnosed Incident Cases of IPF, N, by Sex, Ages ≥18 Years, 2019
Figure 11: 7MM, Diagnosed Incident Cases of IPF by Age, N, Both Sexes, 2019
Figure 12: 7MM, Diagnosed Prevalent Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
Figure 13: 7MM, Diagnosed Prevalent Cases of IPF, N, by Sex, Ages ≥18 Years, 2019
Figure 14: 7MM, Diagnosed Prevalent Cases of IPF by Age, N, Both Sexes, 2019
Figure 15: 7MM, Diagnosed Prevalent Cases of IPF by Severity, N, Both Sexes, Ages ≥18 Years, 2019
Figure 16: 7MM, Total Prevalent Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook